Sirt1 induction confers resistance to etoposide-induced genotoxic apoptosis in thyroid cancers

Kweon,Ki  Hwan; Lee,Cho  Rok; Jung,Soo  Jung; Ban,Eun  Jeong; Kang,Sang-Wook; Jeong,Jong  Ju; Nam,Kee-Hyun; Jo,Young  Suk; Lee,Jandee; Chung,Woong  Youn

doi:10.3892/ijo.2014.2585

Sirt1 induction confers resistance to etoposide-induced genotoxic apoptosis in thyroid cancers

Authors:
- Ki Hwan Kweon
- Cho Rok Lee
- Soo Jung Jung
- Eun Jeong Ban
- Sang-Wook Kang
- Jong Ju Jeong
- Kee-Hyun Nam
- Young Suk Jo
- Jandee Lee
- Woong Youn Chung
View Affiliations

Affiliations: Department of Surgery, Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea, Department of Internal Medicine, Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea
Published online on: August 8, 2014 https://doi.org/10.3892/ijo.2014.2585
Pages: 2065-2075

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite the favorable therapeutic outcomes reported in differentiated thyroid cancer (DTC), a significant proportion of DTC patients present with refractory behavior to conventional therapy. The sirtuin (Sirt) family has recently been implicated in the maintenance of cellular homeostasis under genotoxic stress. Here, we investigated the induction of Sirt1 expression by etoposide-induced genotoxic stress to gain insights into thyroid carcinogenesis and identify novel therapeutic targets. Immunohistochemical staining analyses of Sirt1 and Sirt3 were performed using human thyroid cancer tissues and matched normal tissues, and bioinformatic analyses were done using public repositories, including the Human Protein Atlas, BioGPS, NCBI Gene Expression Omnibus (GEO) profiles, and GeneNetwork. TPC1, FTC133 and FRO cells were used for molecular biological experiments including apoptosis assays, MTT, immunofluorescence staining and qRT-PCR assays. The IHC data and public repositories data consistently showed variable Sirt1 and Sirt3 expression patterns in normal thyroid follicular cells and papillary thyroid cancer cells. The induction of Sirt1 and Sirt3 was cell type-specific and the expression levels of these genes correlated with apoptotic cell death and cell viability after etoposide-induced genotoxic stress. Sirt1‑Foxp3 signaling-mediated regulation of Bax and p21 mRNA expression was a signature molecular event in TPC1 cells, which showed remarkable resistance to etoposide-induced genotoxic stress. The induction of Sirt1 and Sirt3 may be a determinant of thyroid cancer cell survival under genotoxic stress conditions. Further examination of the Sirt1-Foxp3 signal may improve our understanding of thyroid carcinogenesis and help identify new druggable targets.

View Figures

View References

1	Lang BH, Wong KP, Cheung CY, Wan KY and Lo CY: Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis. Ann Surg Oncol. 20:1329–1335. 2013. View Article : Google Scholar : PubMed/NCBI
2	Lin JD, Huang MJ, Juang JH, et al: Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid. 9:1227–1235. 1999. View Article : Google Scholar : PubMed/NCBI
3	Sabra MM, Dominguez JM, Grewal RK, et al: Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab. 98:E829–E836. 2013. View Article : Google Scholar : PubMed/NCBI
4	Droz JP, Schlumberger M, Rougier P, Ghosn M, Gardet P and Parmentier C: Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori. 76:480–483. 1990.PubMed/NCBI
5	Schlumberger M: Target therapies for radioiodine refractory advanced thyroid tumors. J Endocrinol Invest. 35:40–44. 2012.PubMed/NCBI
6	Salvatore G, De Falco V, Salerno P, et al: BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res. 12:1623–1629. 2006. View Article : Google Scholar : PubMed/NCBI
7	Xing M: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 28:742–762. 2007. View Article : Google Scholar : PubMed/NCBI
8	Liu D, Hu S, Hou P, Jiang D, Condouris S and Xing M: Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res. 13:1341–1349. 2007. View Article : Google Scholar : PubMed/NCBI
9	Lito P, Rosen N and Solit DB: Tumor adaptation and resistance to RAF inhibitors. Nat Med. 19:1401–1409. 2013. View Article : Google Scholar : PubMed/NCBI
10	Montero-Conde C, Ruiz-Llorente S, Dominguez JM, et al: Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 3:520–533. 2013. View Article : Google Scholar : PubMed/NCBI
11	Haigis MC and Guarente LP: Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes Dev. 20:2913–2921. 2006. View Article : Google Scholar : PubMed/NCBI
12	Luo J, Nikolaev AY, Imai S, et al: Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 107:137–148. 2001. View Article : Google Scholar : PubMed/NCBI
13	Westerheide SD, Anckar J, Stevens SM Jr, Sistonen L and Morimoto RI: Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science. 323:1063–1066. 2009. View Article : Google Scholar : PubMed/NCBI
14	Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM and Puigserver P: Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 434:113–118. 2005. View Article : Google Scholar : PubMed/NCBI
15	Rodgers JT, Lerin C, Gerhart-Hines Z and Puigserver P: Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett. 582:46–53. 2008. View Article : Google Scholar : PubMed/NCBI
16	Brunet A, Sweeney LB, Sturgill JF, et al: Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 303:2011–2015. 2004. View Article : Google Scholar : PubMed/NCBI
17	Brachmann CB, Sherman JM, Devine SE, Cameron EE, Pillus L and Boeke JD: The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev. 9:2888–2902. 1995. View Article : Google Scholar : PubMed/NCBI
18	Bishop NA and Guarente L: Genetic links between diet and lifespan: shared mechanisms from yeast to humans. Nat Rev Genet. 8:835–844. 2007. View Article : Google Scholar : PubMed/NCBI
19	Raynes R, Brunquell J and Westerheide SD: Stress inducibility of SIRT1 and its role in cytoprotection and cancer. Genes Cancer. 4:172–182. 2013. View Article : Google Scholar : PubMed/NCBI
20	Verdin E: AROuSing SIRT1: identification of a novel endogenous SIRT1 activator. Mol Cell. 28:354–356. 2007. View Article : Google Scholar : PubMed/NCBI
21	Gorospe M and de Cabo R: AsSIRTing the DNA damage response. Trends Cell Biol. 18:77–83. 2008. View Article : Google Scholar
22	Brennan CM and Steitz JA: HuR and mRNA stability. Cell Mol Life Sci. 58:266–277. 2001. View Article : Google Scholar : PubMed/NCBI
23	Lopez de Silanes I, Zhan M, Lal A, Yang X and Gorospe M: Identification of a target RNA motif for RNA-binding protein HuR. Proc Natl Acad Sci USA. 101:2987–2992. 2004.PubMed/NCBI
24	Song NY and Surh YJ: Janus-faced role of SIRT1 in tumorigenesis. Ann NY Acad Sci. 1271:10–19. 2012. View Article : Google Scholar : PubMed/NCBI
25	Bosch-Presegue L and Vaquero A: The dual role of sirtuins in cancer. Genes Cancer. 2:648–662. 2011. View Article : Google Scholar : PubMed/NCBI
26	Yuan J, Luo K, Liu T and Lou Z: Regulation of SIRT1 activity by genotoxic stress. Genes Dev. 26:791–796. 2012. View Article : Google Scholar : PubMed/NCBI
27	Kwon HS, Lim HW, Wu J, Schnolzer M, Verdin E and Ott M: Three novel acetylation sites in the Foxp3 transcription factor regulate the suppressive activity of regulatory T cells. J Immunol. 188:2712–2721. 2012. View Article : Google Scholar : PubMed/NCBI
28	Bollag G, Tsai J, Zhang J, et al: Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 11:873–886. 2012. View Article : Google Scholar : PubMed/NCBI
29	Turajlic S, Ali Z, Yousaf N and Larkin J: Phase I/II RAF kinase inhibitors in cancer therapy. Expert Opin Investig Drugs. 22:739–749. 2013. View Article : Google Scholar : PubMed/NCBI
30	Brilli L and Pacini F: Targeted therapy in refractory thyroid cancer: current achievements and limitations. Future Oncol. 7:657–668. 2011. View Article : Google Scholar : PubMed/NCBI
31	Poulikakos PI, Zhang C, Bollag G, Shokat KM and Rosen N: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 464:427–430. 2010. View Article : Google Scholar : PubMed/NCBI
32	Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 480:387–390. 2011. View Article : Google Scholar : PubMed/NCBI
33	Montagut C, Sharma SV, Shioda T, et al: Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68:4853–4861. 2008. View Article : Google Scholar : PubMed/NCBI
34	Greger JG, Eastman SD, Zhang V, et al: Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 11:909–920. 2012. View Article : Google Scholar : PubMed/NCBI
35	Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 468:968–972. 2010. View Article : Google Scholar : PubMed/NCBI
36	Su F, Bradley WD, Wang Q, et al: Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 72:969–978. 2012. View Article : Google Scholar : PubMed/NCBI
37	Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
38	Atefi M, von Euw E, Attar N, et al: Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 6:e289732011. View Article : Google Scholar : PubMed/NCBI
39	Sanchez-Hernandez I, Baquero P, Calleros L and Chiloeches A: Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. Cancer Lett. 314:244–255. 2012. View Article : Google Scholar : PubMed/NCBI
40	Vergani E, Vallacchi V, Frigerio S, et al: Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia. 13:1132–1142. 2011.PubMed/NCBI
41	Lee MH, Lee SE, Kim DW, et al: Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. J Clin Endocrinol Metab. 96:E19–E30. 2011. View Article : Google Scholar : PubMed/NCBI
42	Lee SE, Lee JU, Lee MH, et al: RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer. Oncogenesis. 2:e552013. View Article : Google Scholar : PubMed/NCBI
43	Uhlen M, Oksvold P, Fagerberg L, et al: Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 28:1248–1250. 2010. View Article : Google Scholar : PubMed/NCBI
44	Zuo S, Liu C, Wang J, et al: IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells. J Cancer Res Clin Oncol. 138:1045–1055. 2012. View Article : Google Scholar : PubMed/NCBI
45	Warfel NA and El-Deiry WS: p21^WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol. 25:52–58. 2013.PubMed/NCBI
46	Deng C, Zhang P, Harper JW, Elledge SJ and Leder P: Mice lacking p21^CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82:675–684. 1995.
47	Gartel AL and Tyner AL: Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res. 246:280–289. 1999. View Article : Google Scholar : PubMed/NCBI
48	Abbas T and Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 9:400–414. 2009. View Article : Google Scholar : PubMed/NCBI
49	van Loosdregt J, Brunen D, Fleskens V, Pals CE, Lam EW and Coffer PJ: Rapid temporal control of Foxp3 protein degradation by sirtuin-1. PLoS One. 6:e190472011.PubMed/NCBI